Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
Abstract Background The programmed death-1/programmed death-ligand-1 (PD-1/PD-L1) immune regulatory axis has emerged as a promising new target for cancer therapeutics, with lasting responses seen in the treatment of metastatic renal and lung carcinomas, as well as melanomas. As tumor surface express...
Saved in:
Main Authors: | Opal L. Reddy (Author), Peter I. Shintaku (Author), Neda A. Moatamed (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2017-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expression of immune checkpoint regulators, programmed death-ligand 1 (PD-L1/PD-1), cytotoxic T lymphocyte antigen 4 (CTLA-4), and indolaimine-2, 3-deoxygenase (IDO) in uterine mesenchymal tumors
by: Alireza Samiei, et al.
Published: (2022) -
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors
by: Kemal KÖSEMEHMETOĞLU, et al.
Published: (2017) -
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018) -
The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
by: Yan Li, et al.
Published: (2019) -
Distribution and Expression of Programmed Death Ligand -1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India
by: Sheba S K JACOB
Published: (2021)